Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
EGX-A
EGX-A is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a full agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and produces antidepressant-like effects in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of January 2024, it is in the preclinical research stage of development.
Hub AI
EGX-A AI simulator
(@EGX-A_simulator)
EGX-A
EGX-A is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a full agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and produces antidepressant-like effects in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of January 2024, it is in the preclinical research stage of development.